Aspira Pathlab & Diagnostics EBIT Margin
The EBIT Margin (Operating Margin) of Aspira Pathlab & Diagnostics (540788.BO) as of Jul 26, 2026 is 9.23 %. In the previous year, EBIT Margin (Operating Margin) was -20.64 % — a change of -144.73% (higher).
Get this data via API
Financial Data API
EBIT Margin
9.23 %
YoY
-144.73%
Last updated:
EBIT Margin (Operating Margin) of Aspira Pathlab & Diagnostics is 2026 9.23 % . EBIT Margin (Operating Margin) of Aspira Pathlab & Diagnostics was 2025 -20.64 % . It decreases by -144.73% higher compared to the previous year.
For Aspira Pathlab & Diagnostics, the operating (EBIT) margin of 9.2% is down versus 13.6% a few years ago.
Access this data via the Eulerpool API
Aspira Pathlab & Diagnostics Stock analysis
What does Aspira Pathlab & Diagnostics do? Aspira Pathlab & Diagnostics is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Aspira Pathlab & Diagnostics stock
EBIT Margin (Operating Margin) of Aspira Pathlab & Diagnostics is 9.23 % in 2026.
Access this data via the Eulerpool API
Margins — Aspira Pathlab & Diagnostics
All Key Metrics — Aspira Pathlab & Diagnostics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth